Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.47 |
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | JAK1 | P23458 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23849720 | 0.88 | TYK2 (0.50) | TYK2JAK2JAK1KCNH2KIT | |
| SCHEMBL21493298 | 0.87 | TYK2 (0.60) | TYK2JAK2JAK1KCNH2KIT | |
| SCHEMBL21493305 | 0.87 | TYK2 (0.52) | TYK2JAK2JAK1KCNH2KIT | |
| SCHEMBL20093260 | 0.84 | TYK2 (0.54) | TYK2 | |
| SCHEMBL23849706 | 0.84 | TYK2 (0.65) | TYK2JAK2JAK1KCNH2KIT | |
| SCHEMBL21493382 | 0.84 | TYK2 (0.57) | TYK2JAK2JAK1 | |
| SCHEMBL21493333 | 0.83 | TYK2 (0.51) | TYK2JAK2JAK1KCNH2KIT | |
| SCHEMBL20112997 | 0.83 | TYK2 (0.60) | TYK2JAK2JAK1KCNH2KIT | |
| SCHEMBL21493307 | 0.83 | TYK2 (0.66) | TYK2JAK2JAK1KCNH2KIT | |
| SCHEMBL29707508 | 0.83 | TYK2 (0.60) | TYK2JAK2JAK1KCNH2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532473-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2021-09-29 | — | — | EP | disclosed |
| US-10781215-B2 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190322672-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781215-B2 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | TYK2, IL2, IL23R | TYK2 1/4885JAK2 9/4885JAK1 8/4885 |
| US-20190322672-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, IFNG | TYK2 1/4885JAK2 12/4885JAK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.